Conditions: Head and Neck Squamous Cell Carcinoma
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 45
Healthy volunteers: no

Brief summary:
The purpose of this trial is to determine whether or not Cialis (tadalafil) administered to head and neck squamous cell cancer patients augments immune response.

Detailed description:

Arms:
arm 1: None arm 2: Tadalafil 20 mg once per day

Interventions: intervention 1: Tadalafil intervention 2: Placebo Pill
Intervention descriptions: intervention 1: 20 mg once daily for 10 - 14 days intervention 2: Placebo

Protocol document: